<DOC>
	<DOCNO>NCT01724879</DOCNO>
	<brief_summary>The current standard treatment approach young patient Positive Acute Lymphoblastic Leukemia ( Ph+ALL ) combination chemotherapy protocol employ four five cytotoxic agent typically use ALL together imatinib . It recommend propose allogeneic Standard Induction Consolidation Therapy ( SCT ) eligible patient suitable donor continue imatinib without additional therapy patient undergoing SCT . This protocol study newly diagnose Philadelphia chromosome positive acute lymphoblastic leukemia patient age 18 55 year . The objective strategy improve overall result treatment adult ALL addition specific molecule common chemotherapeutic schedule .</brief_summary>
	<brief_title>Study Frontline Dasatinib Plus Chemotherapy Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia ( PH+ALL )</brief_title>
	<detailed_description>In present study , potent ABL tyrosine kinase inhibitor , Dasatinib add standard induction consolidation chemotherapy Philadelphia positive chromosome sub-group ALL patient age 18 55 year . The Study hypothesis , Dasatinib combination standard chemotherapy accord GMALL protocol 07/2003 feasible induces cytologic molecular remission rate comparable chemotherapy combination imatinib without increase treatment-related mortality .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Confirmed new diagnosis Philadelphia chromosome BCRABL positive acute lymphoblastic leukemia Male female patient age 1855 year Not previously treat except prephase ( corticosteroid , cyclophosphamide , single dose VCR permit ) therapy establishment diagnosis Signed write inform consent , willingness ability comply study procedure Molecular detection BCRABL transcripts Willingness woman childbearing potential ( WOCBP ) male subject whose sexual partner WOCBP , use effective form contraception ( pearl index &lt; 1 % ) , complete sexual abstinence , combine oral contraceptive , hormone IUCD , vaginal hormone ring , transdermal contraceptive patch , contraceptive implant depot contraceptive injection combination second method contraception like condom cervical cap / diaphragm spermicide surgical sterilisation ( vasectomy ) male patient male partner study least 6 month thereafter . WOCBP define sexually mature woman undergone hysterectomy surgical sterilization naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Negative pregnancy test woman childbearing potential . Patients ECOG status &gt; 2 Patients QTcF &gt; 470 m Cardiac insufficiency NYHA grade III/IV , LEVF &lt; 50 % , myocardial infarction within past 6 month prior study Active secondary malignancy require treatment Patients active , uncontrolled bacterial , viral fungal infection Known infection HIV , Hepatitis B ( except post vaccinal profile ) C Inadequate hepatic function define ASAT ALAT &gt; 2,5 time institutional upper limit normal total bilirubin &gt; 2 fold institutional upper limit unless consider due organ involvement leukemia Concurrent severe disease exclude administration therapy Expected noncompliance inability understand inform consent Female patient pregnant breast feed Treatment investigational antileukemic agent informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>philadelphia chromosome</keyword>
	<keyword>BCR-ABL</keyword>
	<keyword>ALL</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>dasatinib</keyword>
	<keyword>Sprycel</keyword>
</DOC>